{
  "docId": "019de072-4b47-73db-b658-db74b88c61ed",
  "docSlug": "479ed371379fcba7e292c76acd5b0af7",
  "documentTitle": "BioNTech | Results Presentation Deck | 37 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 37,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 48,
  "notes": "Includes patient demographic table, safety/efficacy summaries, and radiographic case studies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4b47-73db-b658-db74b88c61ed/23",
  "deckHref": "/decks/019de072-4b47-73db-b658-db74b88c61ed",
  "deckJsonHref": "/decks/019de072-4b47-73db-b658-db74b88c61ed.json",
  "deckAnchorHref": "/decks/019de072-4b47-73db-b658-db74b88c61ed#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.12,
        "x": 0.85,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Upcoming AACR Presentation, April 10th",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b941797d-0564-4674-a3ed-f68133428b0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.58,
        "y": 0.57
      },
      "kind": "image",
      "text": "Radiographic images of patients",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96ef401b-758d-4562-ac46-cd4dbd1a794b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Safety: CLDN6 CAR-T cells alone or combined with CARVac well tolerated with only 1 DLT observed. CRS grade 1-2 in 1 patient at DL1 + CARVac and 6 patients at DL2, and was manageable by administration of tocilizumab",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1cc2fea3-744a-4bf3-b0a4-57f1566c400e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.04,
        "y": 0.76
      },
      "kind": "paragraph",
      "text": "Efficacy: Robust engraftment of CAR-T cells resulting in a total amount of around 10^9 achieved in most patients and seems predictive for clinical activity. 9 of 10 patients showed initial disease control including 4 PRs; 3 in testicular cancer patients with recent relapse after HDCT/ASCT",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "292d4332-5872-4d6c-9b0f-f9ca1ffc2cfd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.04,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Data cutoff = NOV 18, 2021; CRS, cytokine release syndrome; DL, dose level; DLT, dose-limiting toxicity; HDCT, high dose chemotherapy; ASCT, autologous stem cell transplant...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "993b2880-aa85-4a61-8c5e-02ce1a42463e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.92,
        "x": 0.04,
        "y": 0.205
      },
      "kind": "table",
      "text": "Cohort/Patient Characteristics table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6626bbb3-8e43-49d6-9072-45446c568b1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "BNT211: CAR-T Engraftment and Tolerable Safety Profile with CLDN6 CAR-T without and with CARVac",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ae5508f-150b-4f3a-9cdb-136b10fd6a25",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 22,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "09024b0c-a4d8-4180-8644-ba27fdaa172f",
      "evidence": "The presentation highlights BNT211 as a potential solution for targeting multiple high-need solid tumors",
      "position": 1,
      "objective": "Presenting a potential solution with BNT211: CAR-T Cell Program",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}